Literature DB >> 34051009

The gut microbiota associated with high-Gleason prostate cancer.

Makoto Matsushita1, Kazutoshi Fujita1,2, Daisuke Motooka3, Koji Hatano1, Shota Fukae4, Norihiko Kawamura5, Eisuke Tomiyama1, Yujiro Hayashi1, Eri Banno2, Tetsuya Takao5, Shingo Takada4, Shinichi Yachida6, Hirotsugu Uemura2, Shota Nakamura3, Norio Nonomura1.   

Abstract

We have found that intestinal bacteria and their metabolites, short-chain fatty acids (SCFAs), promote cancer growth in prostate cancer (PCa) mouse models. To clarify the association between gut microbiota and PCa in humans, we analyzed the gut microbiota profiles of men with suspected PCa. One hundred and fifty-two Japanese men undergoing prostate biopsies (96 with cancer and 56 without cancer) were included in the study and randomly divided into two cohorts: a discovery cohort (114 samples) and a test cohort (38 samples). The gut microbiota was compared between two groups, a high-risk group (men with Grade group 2 or higher PCa) and a negative + low-risk group (men with negative biopsy or Grade group 1 PCa), using 16S rRNA gene sequencing. The relative abundances of Rikenellaceae, Alistipes, and Lachnospira, all SCFA-producing bacteria, were significantly increased in high-risk group. In receiver operating characteristic curve analysis, the index calculated from the abundance of 18 bacterial genera which were selected by least absolute shrinkage and selection operator regression detected high-risk PCa in the discovery cohort with higher accuracy than the prostate specific antigen test (area under the curve [AUC] = 0.85 vs 0.74). Validation of the index in the test cohort showed similar results (AUC = 0.81 vs 0.67). The specific bacterial taxa were associated with high-risk PCa. The gut microbiota profile could be a novel useful marker for the detection of high-risk PCa and could contribute to the carcinogenesis of PCa.
© 2021 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.

Entities:  

Keywords:  bacteria; biomarkers; gastrointestinal microbiome; metagenomics; prostate cancer

Year:  2021        PMID: 34051009     DOI: 10.1111/cas.14998

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  6 in total

1.  Mitochondrial Function and Microbial Metabolites as Central Regulators of Intestinal Immune Responses and Cancer.

Authors:  Saskia Weber-Stiehl; Lea Järke; Juan Camilo Castrillón-Betancur; Felix Gilbert; Felix Sommer
Journal:  Front Microbiol       Date:  2022-06-29       Impact factor: 6.064

Review 2.  The Effects and Mechanisms of Flavonoids on Cancer Prevention and Therapy: Focus on Gut Microbiota.

Authors:  Man Wang; Fei Yu; Yuan Zhang; Wenguang Chang; Meng Zhou
Journal:  Int J Biol Sci       Date:  2022-01-24       Impact factor: 6.580

Review 3.  Connecting the Dots Between the Gut-IGF-1-Prostate Axis: A Role of IGF-1 in Prostate Carcinogenesis.

Authors:  Makoto Matsushita; Kazutoshi Fujita; Koji Hatano; Marco A De Velasco; Hirotsugu Uemura; Norio Nonomura
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-15       Impact factor: 5.555

Review 4.  Prostate diseases and microbiome in the prostate, gut, and urine.

Authors:  Makito Miyake; Yoshihiro Tatsumi; Kenta Ohnishi; Tomomi Fujii; Yasushi Nakai; Nobumichi Tanaka; Kiyohide Fujimoto
Journal:  Prostate Int       Date:  2022-03-29

5.  Firmicutes in Gut Microbiota Correlate with Blood Testosterone Levels in Elderly Men.

Authors:  Makoto Matsushita; Kazutoshi Fujita; Daisuke Motooka; Koji Hatano; Junya Hata; Mitsuhisa Nishimoto; Eri Banno; Kentaro Takezawa; Shinichiro Fukuhara; Hiroshi Kiuchi; Yue Pan; Toshifumi Takao; Akira Tsujimura; Shinichi Yachida; Shota Nakamura; Wataru Obara; Hirotsugu Uemura; Norio Nonomura
Journal:  World J Mens Health       Date:  2022-02-24       Impact factor: 6.494

Review 6.  Dysbiotic microbes and how to find them: a review of microbiome profiling in prostate cancer.

Authors:  Paul Vinu Salachan; Karina Dalsgaard Sørensen
Journal:  J Exp Clin Cancer Res       Date:  2022-01-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.